We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Arrowhead Pharmaceuticals said it earned a $100 million milestone payment from Sarepta Therapeutics. The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100-million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). This morning’s news release reported that ...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...